No abstract available.
Bradycardia ; Insufflation ; Laparoscopy

No abstract available.
Bradycardia ; Infarction ; Syncope

No abstract available.
Arthroplasty ; Bradycardia ; Cough ; Hip

No abstract available.
Bradycardia ; Cardiopulmonary Resuscitation ; Cough

BACKGROUND: Dengue is a mosquito-borne viral disease that has been a global burden especially in the tropical regions. Cardiac involvement has been discussed in several studies. This is a pilot study to identify electrocardiogram abnormalities and correlate these with the severity of dengue illness. OBJECTIVES: To evaluate the efficiency of electrocardiogram as a predictive tool for the severity and clinical course of pediatric dengue infections. METHODS: This prospective cohort study was conducted at the Philippine Children’s Medical Center from August to October 2017. A total of 325 dengue consults were seen at the pediatric emergency room during the study period. Of these, 66 pediatric patients fulfilled the inclusion criteria for this study. Serial pediatric electrocardiograms (ECG) were performed on days 1, 7, and 14 afebrile. The ECGs were interpreted according to rhythm, axis and duration of waveforms and intervals. These ECG interpretations were subsequently correlated to the patients’ dengue severity and clinical course. RESULTS: Rhythm abnormalities were found in 15 out of the 66 dengue patients for an overall incidence of 23%. All the rhythms were benign and self-limiting, including sinus bradycardia, tachycardia, and first-degree atrio-ventricular block. Majority of the dengue patients had sinus rhythm (42 of 66, 64%), and of these, 8 had heart rates at the lower limits of normal range for age (12%). 23 percent of abnormal rhythms were detected on day 1 of illness. All rhythm abnormalities resolved by day 14 of afebrile. CONCLUSION: The series of ECG did not show clinically significant or life-threatening arrhythmias during the patients’ dengue illness in this cohort. All arrhythmias were benign and self-limiting, regardless of dengue severity. The ECG did not correlate well with and cannot be utilized to predict the clinical course of the dengue illness. RECOMMENDATIONS A retrospective comparative study is recommended to determine predictability of dengue severity using ECG. A bigger cohort of dengue patients may detect significant arrhythmias not caught in this study.
Severe Dengue ; Bradycardia

Glycopyrrolate is frequently administered in combination with neostigmine to reverse a neuromus- cular blockade. The dosage was well established at 1/5 of neostigmine. But the authers have often observed a delayed manifestation of relative bradycardia after such a recommended dosage. This is not mentioned in the literature, but this may be due to an insufficient observation period. The authors monitored the change of pulse rate for 1 hour after the administration of the recom. mended dose. Further, the data wIns compared with that obtained after studies of lower and higher doses. The doses were 0.004, 0.008 and 0.012mg/kg of glycopyrrolate with 0.04mg/kg of neostigmine. 1) At all doses, bradycardia relative to the pre-reversal pulse rate was progressive until 30 minutes after injection. 2) As the glycopyrrate dose was increased the degree of bradycardia decreased (-24.7, -20.5, - 15.0 at 30 min.). 3) There was no difference in the immediate change in the pulse rate between the dcsages of 0.008 and 0.012 mg/kg. Change occured at 9 mins. 4) At dosages of 0.004 and 0.008 mg/kg, the pulse rates at 60 min were comparable to their ward pulses, but at a dosage of 0.012 mg/kg, the pulse rate was 8.5 beats/min higher.
Bradycardia ; Glycopyrrolate* ; Heart Rate* ; Neostigmine*

No abstract available.
Bradycardia* ; Endoscopy, Digestive System* ; Hypotension* ; Takotsubo Cardiomyopathy*

BACKGROUND: Carvedilol, an antihypertensive agent with beta-blocking and vasodilating pro-perties, has been demonstrated to be effective in reducing blood pressure. The purpose of this study is to compare the antihypertensive efficacy, safety and tolerability of carvedilol and atenolol in patients with stage 1 to 2 essential hypertension. METHODS: In this double-blind, double-dummy, randomized, parallel study, the efficacy, safety and tolerability of once-daily carvedilol versus once-daily atenolol were evaluated in 58 patients for 8 weeks with stage 1-2 hypertension. If mean peak sitting diastolic blood pressure was equal to or greater than 90mmHg after a 4 week treatment period, the dosage for both study drugs were doubled until the end of study. RESULTS: Data from 58 of 73 patients who completed the study were eligible for per-protocol analysis. At 4 weeks post treatment commencement, mean reductions in peak sitting diastolic blood pressure were 13.9mmHg (95% confidence interval 17.1-11.4) with 25mg carvedilol and 13.6mmHg (95% confidence interval 16.8-10.3) with 50mg atenolol. After the 8 week treatment period with dose titration, mean reductions in peak sitting diastolic blood pressure were 14.7mmHg (95% confidence interval 17.8-11.6) with 50mg carvedilol and 13.6mmHg (95% confidence interval 17.3-9.9) with 100mg atenolol. There were no statistically significant differences between the two treatments in the percentage of patients achieving a normalized blood pressure or in the degree of change in mean peak sitting diastolic blood pressure. Safety profiles were similar between treatments. One patient withdrew due to severe bradycardia development during the second week of treatment with atenolol. CONCLUSION: In patients with mild to moderate hypertension, there were no significant differences between the efficacy of carvedilol or atenolol with regard to antihypertensive effect. Both carvedilol and atenolol were well tolerated with similar safety profiles.
Atenolol* ; Blood Pressure ; Bradycardia ; Humans ; Hypertension*

In human volunteers, 0.25mg of atropine was given in divided doses(0.1mg and 0.15mg) with an interval of 15 minutes and 50 minutes When atropine was given with an interval of 15 minutes, the first dose (0.1mg) produced bardycardia and the second does caused slight increase of pulse rate which did not exceed the original rate. When atropine was given with an interval of 50 minutes, the first dose (0.1mg) produced bradycardia and the second dose marked increase of pulse rate which exceeded the original rate.
Atropine* ; Bradycardia ; Healthy Volunteers ; Heart Rate*

No abstract available.
Analgesia* ; Bradycardia* ; Female ; Labor Pain* ; Pregnancy